NCT04312659View on ClinicalTrials.gov

A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions
Crohn Disease
Interventions
DRUG

Infliximab

Participants will be observed who were treated with Infliximab.

Trial Locations (5)

200025

Ruijin Hospital Shanghai Jiao Tong University, Shanghai

201102

Children's Hospital of Fudan University, Shanghai

310052

The Childrens Hospital Zhejiang University School Of Medicine, Hangzhou

450018

Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou

510623

Guangzhou Women And Children's Medical Center, Guangzhou

All Listed Sponsors
lead

Johnson & Johnson (China) Investment Ltd.

INDUSTRY

NCT04312659 - A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease | Biotech Hunter | Biotech Hunter